JP2019531346A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531346A5
JP2019531346A5 JP2019536463A JP2019536463A JP2019531346A5 JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5 JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051410 external-priority patent/WO2018053036A1/en
Publication of JP2019531346A publication Critical patent/JP2019531346A/ja
Publication of JP2019531346A5 publication Critical patent/JP2019531346A5/ja
Priority to JP2022148311A priority Critical patent/JP7656574B2/ja
Pending legal-status Critical Current

Links

JP2019536463A 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法 Pending JP2019531346A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022148311A JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
US62/396,025 2016-09-16
US62/396,015 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148311A Division JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Publications (2)

Publication Number Publication Date
JP2019531346A JP2019531346A (ja) 2019-10-31
JP2019531346A5 true JP2019531346A5 (enExample) 2020-10-22

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536463A Pending JP2019531346A (ja) 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (1) CN109922812A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
JP2021518854A (ja) * 2019-05-08 2021-08-05 ノバルティス アーゲー T1dm及び膵島炎の治療に使用するための抗cd40抗体
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
GB2603330B (en) * 2019-08-19 2023-08-09 Hepagene Therapeutics Hk Ltd Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
KR20220134512A (ko) * 2020-02-24 2022-10-05 헤파진 테라퓨틱스 (에이치케이) 리미티드 헤테로고리형 THR-β 수용체 작용제 화합물 및 이에 대한 제조 방법 및 용도
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2327328T3 (es) * 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
CA2546601A1 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
AU2009330458B2 (en) * 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP6957601B2 (ja) * 2016-04-22 2021-11-02 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用
JP2020500199A (ja) * 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法

Similar Documents

Publication Publication Date Title
JP2019531346A5 (enExample)
RU2020123241A (ru) Полициклические соединения в качестве аллостерических ингибиторов shp2
JP2016509047A5 (enExample)
JP2020506178A5 (enExample)
JP2020536881A5 (enExample)
JP2020515610A5 (enExample)
JP2016505586A5 (enExample)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2019094345A5 (enExample)
JP2019512505A5 (enExample)
JP2017505314A5 (enExample)
JP2009526761A5 (enExample)
JP2007505933A5 (enExample)
JP2020500866A5 (enExample)
JP2013512903A5 (enExample)
JP2017518959A5 (enExample)
JP2013542996A5 (enExample)
JP2016509583A5 (enExample)
JP2019518059A5 (enExample)
JP2019510787A5 (enExample)
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
JP2019500387A5 (enExample)
JP2019521097A5 (enExample)
JP2007515419A5 (enExample)
JP2019530724A5 (enExample)